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In the quest for identification of genes for complex disorders, the functional annotation of 
disease-risk variants in the relevant cell type remains a challenge. Lescoat and colleagues 
(1) pose the question ‘what is a scleroderma macrophage?’ and in view of current literature 
(including the study by Moreno-Moral et al. (2)), argued how the heterogeneous range of 
activated macrophages can vary between target organs of interest and possibly across 
different fibrotic diseases.  
While we share Lescoat’s point of view on the underlying complexity of functional cells in 
disease, it remains open to debate whether GM-CSF or M-CSF-mediated differentiation 
conditions of peripheral blood monocytes are sufficient to fully capture the characteristics of 
these cells in their disease context. As stated by Lescoat et al (1), whether and to which 
extent the in vitro defined M1/M2 macrophage subtypes reflect the context-specific activation 
of macrophages observed in different organs (e.g., skin, lung) in scleroderma remains to be 
demonstrated. In this respect, the proposed spectrum model of human macrophage 
activation (3) argues in favour of a scleroderma-specific macrophage activation profile which 
does not fall into the binary M1/M2 categorization (1). 
The experimental challenges encountered in finding the “best” cell culture conditions for 
modelling disease could be eased by investigating the genetic control of gene expression 
(i.e., expression QTL or eQTL). Theoretically, these studies can test, regardless of culturing 
conditions, whether certain DNA variants affect the expression levels of core susceptibility 
genes expressed by myeloid cells, in general. Recent eQTL studies in humans showed 
context-specific variants (i.e. upon stimulation) in monocytes and macrophages but there is 
also evidence of some transcripts which are regulated by DNA sequence variation (e.g., 
SNPs) independently of the stimulus (4) or the differentiation state of the cell (monocyte vs. 
macrophage). For instance, Fairfax et al. identified GSDMA as an eQTL in activated 
monocytes (4) and Moreno-Moral et al. (Figure 2 in (2)) showed the same gene being under 
local genetic control in M-CSF-derived macrophages isolated from scleroderma patients. 
Notably, GSDMA associates with asthma susceptibility (5) and scleroderma (6). This 
suggests genotype-dependent GSDMA expression in a wider monocyte/macrophage 
compartment, which is likely to be a risk component in these diseases. It is therefore 
plausible that the genetic control of GSDMA mRNA levels will be conserved in both M-CSF 
and GM-CSF-derived scleroderma macrophages but further experiments will be required to 
reach a definite conclusion. 
Interestingly, human monocytes share eQTLs with CD4+ T cells (7) and neutrophils (8), 
indicating that common DNA variants regulate mRNA levels of target genes in multiple 
immune cell types, suggesting the possibility of disease risk variants impacting on the wider 
immune response. As highlighted by Lescoat et al. (1), whether the effect of particular 
disease susceptibility variants on a gene’s mRNA level is also conserved at the protein level 
remains to be examined, and we reckon that additional layers of regulation (e.g., 
posttranscriptional, translational) are likely to be at work. Still, there are examples of robust 
conservation between expression and protein QTLs associated with disease (9). Ultimately, 
the eQTL approach, while informative in linking bona fide disease risk variants with target 
cells (as shown by Moreno-Moral et al. (2)), should be considered in the broader target 
tissue context rather than in specific cell culture conditions (10), and recent advances in 
ATAC-seq, single cell RNA-seq will allow the refinement of causal variants for systemic 
sclerosis in a setting closer to their in vivo context. 
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